drugset / Trial / NCT07388810
Study of Ripertamab in Children With Frequent Relapses or Steroid-Dependent Nephrotic Syndrome
RandomizedParallel-groupOpen-labelTreatment
Summary
This is an open-label randomized controlled trial to evaluate the efficacy and safety of one dose versus two doses of ripertamab in children with frequent relapses or steroid-dependent nephrotic syndrome (FRNS/SDNS).
Timeline
- Start
- 2026-02
- Primary completion
- 2026-12
- Completion
- 2028-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | ripertamab | Monoclonal antibody | 375 mg/m2 | — |
Indications
No indication recorded.